1. Home
  2. VTEX vs KROS Comparison

VTEX vs KROS Comparison

Compare VTEX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

N/A

Current Price

$4.01

Market Cap

561.5M

Sector

Technology

ML Signal

N/A

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

N/A

Current Price

$10.70

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTEX
KROS
Founded
1999
2015
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
561.5M
584.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
VTEX
KROS
Price
$4.01
$10.70
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$5.97
$22.25
AVG Volume (30 Days)
1.2M
359.4K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
146.00
EPS
N/A
2.30
Revenue
N/A
$243,864,000.00
Revenue This Year
$12.64
N/A
Revenue Next Year
$10.57
N/A
P/E Ratio
$43.33
$4.90
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$9.12
52 Week High
$6.82
$22.55

Technical Indicators

Market Signals
Indicator
VTEX
KROS
Relative Strength Index (RSI) 72.84 16.71
Support Level $3.92 N/A
Resistance Level $4.23 $15.21
Average True Range (ATR) 0.18 0.73
MACD 0.10 -0.28
Stochastic Oscillator 84.21 4.46

Price Performance

Historical Comparison
VTEX
KROS

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: